EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition

Guanming Jiang, Xuyi Liu iD, Dou Zhang iD, Zhenying Diao, Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Wan Zhang, Xiumao Yin, Ting Yin, Xiaozhen Wang, Jianping Zhou

International Journal of Nanomedicine · 2025-08 · Volume 20 · 10389-10405

DOI: 10.2147/ijn.s531571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025-08. Verfasst von Guanming Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, 523059, People's Re…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Aniline Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmAniline CompoundsAcrylamidesHumansAnimalsErbB ReceptorsHypoxia-Inducible Factor 1, alpha SubunitCell Line, TumorVascular Endothelial Growth Factor AMiceNanomedicineMice, NudeAntineoplastic AgentsOxygenXenograft Model Antitumor AssaysNanoparticlesMice, Inbred BALB CIndolesPyrimidines

Stichwörter der Autor:innen

epidermal growth factor receptorhypoxia-inducible factornon–small cell lung cancerosimertinib resistancevascular endothelial growth factor

Substanzen

osimertinibErbB ReceptorsHypoxia-Inducible Factor 1, alpha SubunitVascular Endothelial Growth Factor AAniline CompoundsAcrylamidesEGFR protein, humanHIF1A protein, humanAntineoplastic AgentsOxygen

Autor:innen und Institutionen

  • Department of Oncology, Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, 523059, People's Republic of China.
  • Research Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, 523808, People's Republic of China.
  • Dongguan Biomedical Nano Engineering Technology Research Center, Guangdong Medical University, Dongguan, Guangdong, 523808, People's Republic of China.
  • Respiratory department, Tsinghua University Yuquan Hospital, Beijing, 100040, People's Republic of China.
  • Department of Thoracic Surgery, Tenth Affiliated Hospital, Southern Medical University (Dongguan People's hospital), Dongguan, Guangdong, 523059, People's Republic of China.

ORCID-Profile: Xuyi Liu, Dou Zhang

Zitieren

APA

Jiang, G., Liu, X., Zhang, D., Diao, Z., Yang, X., Tan, Q., Chen, S., Zhang, W., Yin, X., Yin, T., Wang, X., & Zhou, J. (2025). A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition. International Journal of Nanomedicine, Volume 20, 10389-10405. https://doi.org/10.2147/ijn.s531571

Vancouver

Jiang G, Liu X, Zhang D, Diao Z, Yang X, Tan Q, et al. A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition. International Journal of Nanomedicine. 2025;Volume 20:10389-10405. doi:10.2147/ijn.s531571

BibTeX
@article{Jiang2025,
  author = {Jiang, Guanming and Liu, Xuyi and Zhang, Dou and Diao, Zhenying and Yang, Xiaojun and Tan, Qinquan and Chen, Shiyuan and Zhang, Wan and Yin, Xiumao and Yin, Ting and Wang, Xiaozhen and Zhou, Jianping},
  title = {A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  volume = {Volume 20},
  pages = {10389--10405},
  doi = {10.2147/ijn.s531571}
}
Kostenlos starten →